Regenerative medicine: On the vanguard of health care

Mayo Clinic Proceedings

Volumn 86, Issue 7, 2011, Pages 600-602

  Terzic, Andre ^a   Folmes, Clifford D ^a   Martinez Fernandez, Almudena ^a   Behfar, Atta ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT STEM CELL; BIOENGINEERING; BONE MARROW TRANSPLANTATION; CELL FATE; EDITORIAL; EMBRYONIC STEM CELL; HUMAN; MEDICAL ETHICS; NUCLEAR REPROGRAMMING; PATIENT SAFETY; PLURIPOTENT STEM CELL; REGENERATIVE MEDICINE; STEM CELL TRANSPLANTATION; TISSUE REGENERATION;

EID: 79959725156     PISSN: 00256196     EISSN: None     Source Type: Journal    
DOI: 10.4065/mcp.2011.0325     Document Type: Editorial

References (25)

1. World Health Organization. New WHO report: deaths from noncommunicable diseases on the rise, with developing world hit hardest: noncommunicable diseases a two-punch blow to development. Published April 27, 2011. http://www.who.int/mediacentre/news/releases/2011/ncds-20110427/en/index.html. Accessed June 1, 2011.
2. Terzic A, Waldman SA. Chronic diseases: the emerging pandemic. Clin Transl Sci. In press.
3. Terzic A, Nelson TJ. Regenerative medicine: advancing health care 2020. J Am Coll Cardiol. 2010;55(20):2254-2257.
4. Nelson TJ, Behfar A, Terzic A. Stem cells: biologics for regeneration. Clin Pharmacol Ther. 2008;84(5):620-623.
5. Bergmann O, Bhardwaj RD, Bernard S, et al. Evidence for cardiomyocyte renewal in humans. Science. 2009;324(5923):98-102.
6. Nelson TJ, Behfar A, Terzic A. Strategies for therapeutic repair: the "R3" regenerative medicine paradigm. Clin Transl Sci. 2008;1(2):168-171.
7. Nelson TJ, Behfar A, Yamada S, Martinez-Fernandez A, Terzic A. Stem cell platforms for regenerative medicine. Clin Transl Sci. 2009;2(3):222-227.
8. Behfar A, Crespo-Diaz R, Nelson TJ, Terzic A, Gersh BJ. Stem cells: clinical trials results the end of the beginning or the beginning of the end? Cardiovasc Hematol Disord Drug Targets. 2010;10(3):186-201.
9. Undale AH, Westendorf JJ, Yaszemski MJ, Khosla S. Mesenchymal stem cells for bone repair and metabolic bone diseases. Mayo Clin Proc. 2009;84(10):893-902.
10. Gersh BJ, Simari RD, Behfar A, Terzic CM, Terzic A. Cardiac cell repair therapy: a clinical perspective. Mayo Clin Proc. 2009;84(10):876-892.
11. Abdel-Latif A, Bolli R, Tleyjeh IM, et al. Adult bone marrow-derived cells for cardiac repair: a systematic review and meta-analysis. Arch Intern Med. 2007;167(10):989-997. (Pubitemid 46835786)
12. Terzic A, Perez-Terzic C. Cell therapy for heart failure. Rev Esp Cardiol. 2010;63(10):1117-1119.
13. Simari RD, Moyé LA, Skarlatos SI, et al. Development of a network to test strategies in cardiovascular cell delivery: the NHLBI-sponsored Cardiovascular Cell Therapy Research Network (CCTRN). J Cardiovasc Transl Res. 2010;3(1):30-36.
14. Behfar A, Yamada S, Crespo-Diaz R, et al. Guided cardiopoiesis enhances therapeutic benefit of bone marrow human mesenchymal stem cells in chronic myocardial infarction. J Am Coll Cardiol. 2010;56(9):721-734.
15. Waldman SA, Terzic A. Molecular therapy drives patient-centric health care paradigms. Clin Transl Sci. 2010;3(4):170-171.
16. Yamanaka S, Blau HM. Nuclear reprogramming to a pluripotent state by three approaches. Nature. 2010;465(7299):704-712.
17. Zacharias DG, Nelson TJ, Mueller PS, Hook CC. The science and ethics of induced pluripotency: what will become of embryonic stem cells? Mayo Clin Proc. 2011;86(7):634-640.
18. Nelson TJ, Martinez-Fernandez A, Yamada S, Perez-Terzic C, Ikeda Y, Terzic A. Repair of acute myocardial infarction by human stemness factors induced pluripotent stem cells. Circulation. 2009;120(5):408-416.
19. Martinez-Fernandez A, Nelson TJ, Yamada S, et al. iPS programmed without c-MYC yield proficient cardiogenesis for functional heart chimerism. Circ Res. 2009;105(7):648-656.
20. Thatava T, Nelson TJ, Edukulla R, et al. Indolactam V/GLP-1-mediated differentiation of human iPS cells into glucose-responsive insulin-secreting progeny. Gene Ther. 2011;18(3):283-293.
21. Rosenzweig A. Illuminating the potential of pluripotent stem cells. N Engl J Med. 2010;363(15):1471-1472.
22. Inoue H, Yamanaka S. The use of induced pluripotent stem cells in drug development. Clin Pharmacol Ther. 2011;89(5):655-661.
23. Nelson TJ, Terzic A. Induced pluripotent stem cells: an emerging theranostics platform. Clin Pharmacol Ther. 2011;89(5):648-650.
24. Nelson TJ, Martinez-Fernandez A, Terzic A. Induced pluripotent stem cells: developmental biology to regenerative medicine. Nat Rev Cardiol. 2010;7(12):700-710.
25. Terzic A, Edwards BS, McKee KC, Nelson TJ. Regenerative medicine: a reality of stem cell technology. Minn Med. 2011;94(5):44-47. http://www.minnesotamedicine.com/CurrentIssue/RegenerativeMedicineMay2011/tabid/ 3765/Default.aspx. Accessed June 1, 2011.